Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according…